Jody A. Charnow

Editor

Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.

All articles by Jody A. Charnow

American Transplant Congress

SGLT2 Inhibitors Safe for KTRs, Data Show

Jody A. Charnow

June 24, 2022

The safety profile of SGLT2 inhibitors in kidney transplant recipients with type 2 diabetes is similar to that of other patient populations, new research suggests.

Prostate Cancer

Novel Drug Improves Outcomes vs Bicalutamide in Metastatic Hormone-Sensitive Prostate Cancer

Jody A. Charnow

June 17, 2022

SHR3680 plus ADT improved radiographic progression-free survival and overall survival, when compared with bicalutamide plus ADT.

Prostate Cancer

Second Primary Cancers Less Likely With IMRT vs CRT for Prostate Tumors

Jody A. Charnow

June 15, 2022

Among patients receiving radiation therapy (RT) for prostate cancer, intensity-modulated radiation therapy is significantly associated with a reduced risk for second primary solid malignancies compared with 3D conformal RT.

Prostate Cancer

Enzalutamide’s Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer Confirmed

Jody A. Charnow

June 13, 2022

Updated findings from the ENZAMET trial show that adding enzalutamide to testosterone suppression offers clinically meaningful improvements in overall survival.

Hepatitis C in CKD: Challenges and Opportunities

American Transplant Congress

Kidney Transplant Outcomes Similar Regardless of Donor HCV Status

Jody A. Charnow

June 10, 2022

In a study, aviremic recipients of HCV-positive and HCV-negative deceased donor kidneys had similar 12-month transplant outcomes.

Prostate Cancer

Lutetium-177 PSMA Is a Suitable Option for Post-Docetaxel mCRPC

Jody A. Charnow

June 10, 2022

Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and better patient-reported quality-of-life.

American Transplant Congress

Diabetes in Kidney Transplant Recipients Ups Risk for Overall Graft Loss

Jody A. Charnow

June 9, 2022

The increased death risk associated with type 2 diabetes in kidney transplant recipients does not vary significantly by body mass index, according to investigators.

Bladder Cancer

Tislelizumab Shows Promise for High-Risk Nonmuscle-Invasive Bladder Cancer

Jody A. Charnow

June 9, 2022

Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.

American Transplant Congress

SOT Recipients Differ in Risks for COVID-19-Related ICU Admission

Jody A. Charnow

June 8, 2022

Study findings “have implications for development of SOT-specific approaches for risk stratification that may be applied to patient evaluation and triage,” according to investigators.